LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.45 6.62

Buy Sell

Overview

Share price change

24h

Current

Min

1.3599999999999999

Max

1.47

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+179.56% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.2M 173M
Previous open	-5.17
Previous close	1.45

News Sentiment

By Acuity

20%

80%

37 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 mar 2026, 23:39 UTC

Hot Stocks

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Earnings

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Earnings

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Earnings

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Major News Events

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Earnings

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Rev $19.31B >AVGO

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

179.56% upside

12 Months Forecast

Average 3.83 USD 179.56%

High 7 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

37 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.